Cargando…

Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study

BACKGROUND: Treatment failure frequently occurs in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) who respond to EGFR tyrosine kinase inhibitors initially. This retrospective study tried to investigate the efficacy and safety of apatinib plus icotinib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Jianping, Liu, Xiaoyan, Yang, Sheng, Zhang, Xiangru, Shi, Yuankai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648303/ https://www.ncbi.nlm.nih.gov/pubmed/29075129 http://dx.doi.org/10.2147/OTT.S142686

Ejemplares similares

Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma
por: Xu, Jianping, et al.
Publicado: (2016)

Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation
por: Xia, Pinghui, et al.
Publicado: (2018)

Treating advanced non-small-cell lung cancer in Chinese patients: focus on icotinib
por: Liang, Jun-Li, et al.
Publicado: (2014)

Efficacy of icotinib in advanced lung squamous cell carcinoma
por: Liang, Shuai, et al.
Publicado: (2018)

Icotinib Is an Active Treatment of Non-Small-Cell Lung Cancer: A Retrospective Study
por: Chen, Xiaofeng, et al.
Publicado: (2014)

Icotinib as initial treatment in lung adenocarcinoma patients with brain metastases
por: Xu, Jian‐ping, et al.
Publicado: (2016)

Non-significant efficacy of icotinib plus pleurodesis in epidermal growth factor receptor positive mutant lung cancer patients after malignant pleural effusion drainage compared to icotinib alone
por: Xu, Yunhua, et al.
Publicado: (2020)

Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer
por: Shen, Yan-Wei, et al.
Publicado: (2016)

The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study
por: Hu, Xingsheng, et al.
Publicado: (2015)

An active treatment of lung adenocarcinoma cancer with brain metastases: icotinib
por: Zhang, Ying, et al.
Publicado: (2015)

Prognosis prediction of icotinib as targeted therapy for advanced EGFR-positive non–small cell lung cancer patients
por: Tan, Xueyun, et al.
Publicado: (2023)

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
por: Liu, Kejun, et al.
Publicado: (2020)

Dual Loading of Nanoparticles with Doxorubicin and Icotinib for the Synergistic Suppression of Non-Small Cell Lung Cancer
por: Li, Ke, et al.
Publicado: (2020)

Long-term safety of icotinib in patients with non-small cell lung cancer: a retrospective, real-world study
por: Zhang, Wen, et al.
Publicado: (2020)

Inhibition of miR-22 enhanced the efficacy of icotinib plus pemetrexed in a rat model of non-small cell lung cancer
por: Zhang, Jing, et al.
Publicado: (2020)

Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer
por: Sun, Sheng-Jie, et al.
Publicado: (2022)

Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy
por: Wang, Hanping, et al.
Publicado: (2018)

Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases
por: Xu, Jianping, et al.
Publicado: (2020)

A meta-analysis for the efficacy and safety of icotinib combined with radiotherapy in treating brain metastases of non-small cell lung cancer
por: Zhang, Bo
Publicado: (2023)

The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer
por: Wang, Long, et al.
Publicado: (2021)

A Phase I Study of the Safety and Pharmacokinetics of Higher-Dose Icotinib in Patients With Advanced Non-Small Cell Lung Cancer
por: Liu, Jian, et al.
Publicado: (2016)

Effects of Docetaxel Combined with Icotinib on Serum Tumor Markers and Quality of Life of Patients with Advanced Non-Small Cell Lung Cancer
por: LIN, Huawei, et al.
Publicado: (2020)

Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non‐small cell lung cancer with sensitive EGFR mutations
por: Zhang, Yun, et al.
Publicado: (2021)

Sequentially administrated of pemetrexed with icotinib/erlotinib in lung adenocarcinoma cell lines in vitro
por: Feng, Xiuli, et al.
Publicado: (2017)

Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma [Corrigendum]
Publicado: (2017)

Icotinib and pemetrexed in treatment of lung adenocarcinoma and the effects on prognostic survival rate of patients
por: Zhou, Xueheng, et al.
Publicado: (2019)

Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling
por: Sun, Xiang, et al.
Publicado: (2018)

Trial-Based Cost-Utility Analysis of Icotinib versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China
por: Zhang, Chunxiang, et al.
Publicado: (2016)

Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies
por: Biaoxue, Rong, et al.
Publicado: (2016)

Effect of Wellness Education on Quality of Life of Patients With Non–Small Cell Lung Cancer Treated With First-Line Icotinib and on Their Family Caregivers
por: Li, Yanwei, et al.
Publicado: (2019)

Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations
por: Liang, Wenhua, et al.
Publicado: (2014)

Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China
por: Lu, Shun, et al.
Publicado: (2016)

Effective treatment with icotinib in lung adenocarcinoma with EGFR and ALK co-alterations and brain metastasis
por: Ye, Chenyang, et al.
Publicado: (2016)

Efficacy of combined icotinib and pemetrexed in EGFR mutant lung adenocarcinoma cell line xenografts
por: Cui, Jiadong, et al.
Publicado: (2018)

Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy
por: Feng, Siyang, et al.
Publicado: (2015)

Effects of icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and brain metastases
por: Fan, Yun, et al.
Publicado: (2017)

Bisdemethoxycurcumin Enhances the Sensitivity of Non-small Cell Lung Cancer Cells to Icotinib via Dual Induction of Autophagy and Apoptosis
por: Xiang, Min, et al.
Publicado: (2020)

Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations
por: Yao, Shuyang, et al.
Publicado: (2016)

Effect of icotinib on advanced lung adenocarcinoma patients with sensitive EGFR mutation detected in ctDNA by ddPCR
por: Chen, Hua-Fei, et al.
Publicado: (2019)

Survival benefit and toxicity profile of adjuvant icotinib for patients with EGFR mutation-positive non-small cell lung carcinoma: a retrospective study
por: Zeng, Ziqing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m4ecp9sn4rg9n59rht4kvnt2a8